IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast Featuring Matt Stang, CEO of Delic Holdings Corp.

NEXT STORY
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes
PREV STORY
Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease

European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer ...

author_avatar
NASDAQ Market News

Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer

author_avatar
NASDAQ Market News

InnerScope Hearing (OTC: INND) Signs an LOI to License Audio Cardio Inc. Sound Therapy Tech to Deploy a Subscription-Based App

author_avatar
NASDAQ Market News